ProjectIZEPHA GRK 2019-2022 – Membranassoziierte Arzneimitteltargets für die individualisierte Tumortherapie

Basic data

Acronym:
IZEPHA GRK 2019-2022
Title:
Membranassoziierte Arzneimitteltargets für die individualisierte Tumortherapie
Duration:
01/12/2018 to 30/06/2022
Abstract / short description:
As a major advance towards training the next generation of experts that will tailor pharmacological treatment regimens to the individual genetic makeup, the ICEPHA has established a graduate program focusing on “Membrane-associated Drug Targets in Personalized Cancer Medicine”. Since the launch of the program in 2014, our young graduates work on different aspect of tumor cell biology, on risk and prognosis prediction, and the molecular mechanisms of resistance to cancer therapy. This research is designed to bridge the gap that exists between discovery and translation, allowing a rapid integration of our results into clinical practice in order to improve outcomes for people with cancer i.e. breast cancer, hepatocellular carcinoma, glioblastoma, and other tumor entities.
Keywords:
Drug Targets
Cancer
Translation
personalized medicine
Personalisierte Medizin

Involved staff

Managers

Faculty of Science
University of Tübingen
Pharmaceutical Institute
Department of Pharmacy and Biochemistry, Faculty of Science

Contact persons

Faculty of Science
University of Tübingen
Pharmaceutical Institute
Department of Pharmacy and Biochemistry, Faculty of Science
Baden-Württemberg Center for Brazil and Latin America
Branch offices and other central facilities
Cluster of Excellence: Image-Guided and Functionally Instructed Tumor Therapies (iFIT)
Centers or interfaculty scientific institutions

Local organizational units

Pharmaceutical Institute
Department of Pharmacy and Biochemistry
Faculty of Science

Funders

Stuttgart, Baden-Württemberg, Germany
Help

will be deleted permanently. This cannot be undone.